Company Overview

Developing and commercialising innovative, evidence-based products for gastrointestinal health where there is unmet need.

Directors and Management

Ms Sue MacLeman

Non-Executive Chairman,Non-Executive Director 01/09/2018

Ms MacLeman has more than 30 years' experience as a pharmaceutical, biotechnology and medical technology executive with senior roles in corporate, medical, commercial and business development. She is Member of the audit and risk management committee and member of the remuneration and nominations committee.

BPharm, MMrkg, FACPP, FAICD, PG(ComLaw,CorpGov,BA& Female

Dr David Lionel Brookes

Non-Executive Director 23/01/2019

Dr Brookes has experience in the health and biotechnology industries, first becoming involved in the biotechnology sector in the late 1990's as an analyst. Dr. Brookes has since held Board positions in numerous ASX listed biotechnology companies, including Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI $9B biotech company) in June 2018. He has also Chaired and been a Member of a number of risk and audit committees in ASX listed companies. He is currently a Non-Executive Director of Factor Therapeutics (ASX: FTT) as well as Non-Executive Chairman of the Better Medical group(unlisted). Dr. Brookes maintains roles as a clinician and as a biotechnology industry consultant. Dr Brookes, MBBS (Adelaide), is a Fellow of the Australian College of Rural and Remote Medicine and a Fellow of the Australian Institute of Company Directors. He is Chair of the audit and risk management committee and Member of the remuneration and nominations committee.

MBBS,FACRRM,FAICD Male

Dr Jane Ryan

Non-Executive Director 01/09/2018

Dr Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries where she has held executive roles in management of research and development programs as well as business development and alliance management. Dr Ryan has worked in Australia, the United States and United Kingdom with companies including Peptech, Roche, Cambridge Antibody Technology and Biota Holdings. Throughout her career, she has led many successful fundraising campaigns and licensing initiatives including the awarding of a $230 million US Government contract. Dr Ryan was previously a Board Member of the Victorian endowment for Science Knowledge and Innovation (veski), Diabetes Victoria, TechInSA, and the Diabetes Vaccine Development Centre. Dr Ryan is assisting CSIRO with its GMP protein manufacture initiative. Dr Ryan Member of the audit and risk management committee Chair of the remuneration and nominations committee.

Female

Top 20 Shareholders

Director Transactions